Is ceftriaxone (Ceftriaxone) hepatotoxic?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 30, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Is Ceftriaxone Hepatotoxic?

Ceftriaxone is generally considered safe for use in patients with liver disease and is not classified as a hepatotoxic antibiotic, though rare cases of liver injury have been documented. 1, 2

Safety Profile in Liver Disease

Third-generation cephalosporins, including ceftriaxone, are recommended as first-line antibiotics for patients with liver impairment because they do not require dosage adjustments in hepatic dysfunction and are considered among the safest options. 1

  • The American College of Physicians specifically recommends third-generation cephalosporins as safe antibiotics for patients with liver impairment 1
  • The European Association for the Study of the Liver (EASL) guidelines recommend ceftriaxone as a first-line option for treating bacterial infections in patients with decompensated liver disease 1
  • Standard dosing of ceftriaxone (1-2g daily) is appropriate even in patients with decompensated liver disease 1

Documented Hepatotoxicity Risk

While ceftriaxone is considered safe, hepatotoxicity can occur but is uncommon:

  • The FDA label notes that dosage adjustments are not necessary in patients with hepatic dysfunction alone; however, caution should be exercised in patients with both hepatic dysfunction and significant renal disease, with doses not exceeding 2g daily in this specific population. 3
  • Rare cases of liver injury have been reported, with one retrospective study showing a 19.7% incidence of liver injury when ceftriaxone was combined with other hepatically-metabolized medications 4
  • Isolated case reports document acute drug-induced liver injury from ceftriaxone, though these are uncommon 5

Clinical Manifestations When Hepatotoxicity Occurs

When liver injury does occur with ceftriaxone, it typically presents as:

  • Mild biochemical abnormalities to acute liver injury 5
  • Marked direct hyperbilirubinemia, particularly in patients with underlying conditions like sickle cell disease 6
  • The FDA label lists elevations of alkaline phosphatase (6.1%), AST (3.1%), and ALT (3.3%) as adverse reactions, though these are often transient 3, 7

Important Caveats

Liver function abnormalities with ceftriaxone are sometimes associated with "sludging" of drug in the gallbladder rather than true hepatotoxicity. 8

  • Ceftriaxone-calcium precipitates in the gallbladder can appear on imaging and may cause symptoms of gallbladder disease, which is reversible upon discontinuation 3
  • Biliary lithiasis and gallbladder sludge are recognized adverse reactions that can mimic hepatobiliary disease 3, 7

Monitoring Recommendations

  • In patients with both severe renal and hepatic dysfunction, close clinical monitoring for safety and efficacy is advised 3
  • Monitor prothrombin time during ceftriaxone treatment in patients with impaired vitamin K synthesis or low vitamin K stores (e.g., chronic hepatic disease and malnutrition) 3
  • Vitamin K administration (10 mg weekly) may be necessary if prothrombin time is prolonged 3

Comparison to Truly Hepatotoxic Antibiotics

Ceftriaxone stands in stark contrast to antibiotics that should be avoided in liver disease, such as macrolides, rifampicin, and isoniazid, which carry significant hepatotoxicity risk. 1

  • Macrolides can cause intrahepatic cholestasis and should be used with extreme caution 1
  • Rifampicin and isoniazid require significant caution due to hepatotoxicity risk 9, 1

References

Guideline

Antibiotic Use in Patients with Liver Impairment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Antibiotic Recommendations for Patients with Cirrhosis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Adverse Reactions of Ceftriaxone

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.